Endovastec™, a Subsidiary of MPSC, Listed on the STAR Market of the Shanghai Stock Exchange

Shanghai MicroPort Endovascular MedTech Co., Ltd. ("Endovastec™", or "the Company"), which is a subsidiary of MicroPort Scientific Corporation ("MPSC"), was listed on the STAR Market (Stock code: 688016) of the Shanghai Stock Exchange on July 22, becoming one of the few medical device companies in the first batch of 25 companies to be listed on the market.

Endovastec™ was founded in 2012 and is mainly engaged in the development, manufacturing and sales of aortic and peripheral vascular intervention devices. In the area of aortic intervention devices, the Company is one of the major players that have presented a complete range of products, leading scale and strong competitiveness in the Chinese market, with the main products being aortic stent graft systems. In the area of peripheral vascular intervention devices, the Company boasts a long standing presence and currently has product offerings including peripheral vascular stent systems and peripheral vascular balloon dilation catheters. In addition, the Company's stent graft system in surgical operation is the only device that has been approved to be applied in thoracic aortic dissection procedures in China. After years of development, Endovastec™ products cover over 700 hospitals in more than 30 provinces in China. Meanwhile, the Company has been proactively exploring the overseas markets and is currently exporting products to South America.

With regards to scientific researches, Endovastec™ constantly adheres to the R&D and innovation on the products featuring independent intellectual properties and proactively applies for patent protection for its technological innovation. As of March 31, 2019, the Company possessed 86 patents that had been awarded in China or overseas, with 61 awarded in China (specifically 43 invention patents, 16 utility model patents and 2 design patents) and 25 awarded overseas (all being invention patents).
VitaFlow® Transcatheter Aortic Valve and Delivery System Receives NMPA Approval

On July 12th, Shanghai MicroPort CardioFlow Medtech Co., Ltd. ("MicroPort® CardioFlow"), which is a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort™"), received the registration certificate for the independently developed VitaFlow® Transcatheter Aortic Valve and Delivery System ("VitaFlow™") from National Medical Products Administration of China (NMPA). VitaFlow® is the sixth product of MicroPort® which has successfully obtained the NMPA approval after being granted entry into the Special Review and Approval Procedure for Innovative Medical Devices, which is also known as the Green Path, with NMPA.

VitaFlow® is composed of aortic valve, delivery system, loading tool, balloon catheter and introducer set. Its aortic valve is the first approved to be made of self-expanding bovine pericardial leaflets in China. It applies an innovative design of double layer skirts to more effectively reduce the occurrence of paravalvular leak. The hybrid density cells and nitinol frame enable the valve to effectively expand the calcified leaflets and ensure a stable and precise valve coaxial deployment. The large cells enable coronary access for PCI treatment. VitaFlow® also applies motorized delivery system to facilitate the manipulation of guidewire while deploying the valve by one operator. The delivery system catheter is designed with extraordinary combination of softness and strength, both reducing vascular complications and ensuring the stability and precision of deployment. VitaFlow® is accompanied with MicroPort® CardioFlow’s independently developed balloon catheter and introducer set to further provide the doctors with a comprehensive integrated therapeutic solution to increase the safety and efficacy of the procedure.
MicroPort® Orthopedics Announces Launch of its Evolution® NitrX™ Knee

MicroPort® Orthopedics, a medical device company that develops and manufactures cutting edge joint replacement implants designed to help patients achieve full function faster, recently announced the launch of the Evolution® NitrX™ Medial-Pivot Knee System.

The MicroPort® Orthopedics medial-pivot knee system now stands on over 20 years of clinically demonstrated success with its novel medial-pivot design built on the evidence of the natural stability and kinematic motion of the knee.

The Evolution® NitrX™ Medial-Pivot Knee features a titanium niobium nitride (TiNbN) coating that has been shown in simulated clinical testing to reduce the release of cobalt (Co), chromium (Cr), molybdenum (Mb), and nickel (Ni) ions common in standard CoCr implants. The Evolution® NitrX™ Medial-Pivot Knee builds upon the same medial-pivot legacy of 95% patient satisfaction with 98.8% survivorship at 17 years.
MicroPort1 EP Obtains Approval for OptimAblate™ Cardiac RF Generator from National Medical Products Administration of China (NMPA)

Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort® EP”) recently obtained the registration certificate for its independently developed OptimAblate™ Cardiac RF Generator from National Medical Products Administration of China (NMPA).

The OptimAblate™ Cardiac RF Generator is used to provide radiofrequency energy for catheter radiofrequency ablation in the treatment of tachyarrhythmia. The high-frequency energy heats tissues to block or damage abnormal pathway and restore sinus rhythm. The OptimAblate™ Cardiac RF Generator applies a tilted wide-angle screen and a high-definition touchscreen with a friendly and intuitive interface. When it communicates with Columbus® 3D EP Navigation System (“Columbus®”), the OptimAblate™ Cardiac RF Generator can display capacity, temperature, impedance and ablation time on the same multi-channel screen during the operations, which increases convenience for the doctors to operate the devices. When the irrigated ablation catheter is selected, the OptimAblate™ Cardiac RF Generator can interact with OptimAblate™ Irrigation Pump to display and operate high and low irrigation velocity, and to provide multiple personalized settings and storage of ablation parameters.

Previously, OptimAblate™ Cardiac RF Generator had obtained approvals for launch in the overseas markets after receiving the CE mark in Europe. The NMPA approval is significant in that one more device-category product of MicroPort® EP will officially enter the Chinese market following Columbus® and OptimAblate™ Irrigation Pump.
First implantation of FireHawk® in France

July 19, 2019 - MicroPort® announced that Firehawk® Rapamycin Target Eluting Coronary Stent System “Firehawk™” has been implanted for the first time in France on July 17. Previously, Firehawk® has obtained reimbursement from the French Economic Committee for Health Products (CEPS) in France on May 24, 2019.

This positive outcome is based on the convincing clinical data from the Firehawk® TARGET All-Comers (TARGET AC) trial, a prospective, multi-center, randomized controlled clinical trial consisting of entirely European-based patients with ischemic coronary artery disease. In September 2018, the 12-month results of the Firehawk® TARGET AC trial were published in the world leading medical journal the Lancet. This is the first time that clinical data from a China manufactured drug eluting stent has been published in the Lancet since its first publication nearly 200 years ago. In May 2019, MicroPort® announced 24-month follow-up results at EuroPCR 2019, which will be supported by a concomitant publication in the Journal of the American College of Cardiology (JACC).
Firehawk® TARGET SAFE
Critical Study Completes First Enrollments

The kick-off meeting of the Firehawk® TARGET SAFE critical study on the patients with coronary artery diseases and high bleeding risks, who are undergoing percutaneous coronary intervention (PCI) therapy, was held at the General Hospital of Chinese PLA’s Northern War Zone on July 1, 2019.

The TARGET SAFE trial is a prospective, double-blind, multi-center, randomized controlled critical clinical trial focused on the patients with coronary artery diseases and high bleeding risks, who are undergoing PCI therapy. The study plans to recruit 1,720 subjects at up to 40 hospitals in China. All subjects meeting the inclusion criteria will be 1:1 randomized into the trial. The subjects with successful Firehawk® implantation will have the equal opportunity to be allocated to the 1-month or 6-month dual antiplatelet therapy (DAPT) group. The primary study endpoint is net adverse clinical and cerebral events ("NACCE") rate at 12 months. The secondary endpoints include the incidence of major adverse cardiovascular and cerebrovascular events ("MACCE"), all-cause mortality, major bleeding (BARC definition), as well as the economic endpoint, which is the cost and benefit ratio of subjects at 12 months after the randomization. Subjects in TARGET SAFE will be followed for 24 months.

On July 5, the TARGET SAFE study successfully enrolled the first two subjects, marking the beginning of the clinical enrollment of the project. Dr. Ming Zheng -MicroPort® Vice President, Clinical Science & Medical Affairs, and Dean of MicroPort® Knowledge & Action Medical Training Institute - commented, “We believe that the TARGET SAFE study will become a major landmark study in the field of drug-eluting stent study. It will provide a safe and effective therapeutic strategy for the patients with high bleeding risk undergoing PCI therapy.”

Beijing, China – The 5th Annual Scientific Session of Chinese Stroke Association & Tiantan International Stroke Conference (CSA&TISC 2019), which is one of the most authoritative event focused on cerebrovascular in China, was held at the China National Convention Center recently. MicroPort NeuroTech (Shanghai) Co., Ltd. (“MicroPort® NeuroTech”) showcased three innovative devices including Tubridge® Vascular Reconstruction Device (“Tubridge®”) at CSA&TISC 2019 and presented live cases during the session of operation live streaming.

The APOLO™ device was launched in China in 2004 ahead of its American competitor. The WILLIS® device is China’s first stent graft device approved for launch to treat intracranial aneurysms in China. The Tubridge® device is the first Chinese-made vascular reconstruction device approved for launch in China. Since its launch in 2018, Tubridge® has won recognition of healthcare professionals from dozens of renowned Chinese hospitals and been rapidly applied clinically. A multi-center clinical study has indicated that the aneurysm blocking rates achieved by Tubridge® are significantly higher than those by the conventional embolization. As a leading innovation-driven high-end medical device company in China, MicroPort® NeuroTech will continue to adhere to the development rationale featuring independent innovation to create high-quality medical devices, so as to provide patients and doctors with more comprehensive therapeutic solutions in the field of cerebrovascular intervention.
MicroPort® Orthopedics Celebrates 10th Anniversary and Inaugurates MicroPort® Suzhou Renshoutang Center for Education and Training

On July 19, 2019, MicroPort® Orthopedics, a subsidiary of MicroPort Scientific Corporation ("MicroPort®"), held a ceremony to celebrate its 10th anniversary at its China Headquarters in the Suzhou Industrial Park ("SIP") in Suzhou, China. The MicroPort® Suzhou Renshoutang Center for Education and Training was inaugurated during the ceremony, as was the Center for Orthopedic Innovation under a talent program of China’s Ministry of Human Resource and Social Security.

The MicroPort® Suzhou Renshoutang Center for Education and Training was inaugurated during the ceremony, as was the Center for Orthopedic Innovation under a talent program of China’s Ministry of Human Resource and Social Security. The two centers will provide services and facilities for the exchanges and cooperation between MicroPort® Orthopedics, universities, scientific institutes and healthcare professionals in the future. Specifically, the MicroPort® Suzhou Renshoutang Center for Education and Training is one of the few large-scale and modern training centers for medical device application in China. It covers a floor area of 8,000 square meters and is well equipped with advanced devices for medical training. Over 17,000 persons are predicted to receive trainings at the center every year.
Mr. Rodrigo Pérez Estrada Joins MicroPort® as Vice President Global Branding

Mr. Rodrigo Pérez Estrada has recently joined MicroPort® as Vice President Global Branding. In his new role Mr. Pérez will be responsible for strengthening and integrating the global MicroPort® brand across geographies and subsidiaries. Mr. Pérez is based in France.

Before joining MicroPort® Mr. Pérez was the Head of Cardiovascular, Diabetes and Metabolism globally for Mylan. During the course of his 16-year career Mr. Pérez has held sales, marketing and commercial roles with a local, regional and global scope located in Latin America, US, Europe and Japan for companies like Abbott and Mylan.

Mr. Pérez holds a Bachelor of Business Administration in Marketing and Business Administration from Universidad Panamericana in Mexico.

MicroPort® Chief Operating Officer Ms. Glendy Wang said, “Mr. Pérez owns rich experience and deep insight with respect to global branding. I believe that his joining MicroPort® will provide new momentum for the company to explore brand internationalization and help MicroPort® convey its branding of ‘Where the patient comes first’ better worldwide.”
For more information, please contact:

**Martin Sun**  
Chief Financial Officer  
MicroPort Scientific Corporation  
Tel: (86)(21) 38954600  
Email: ir@microport.com

**Leanne Li**  
Board Secretary & VP of Corporate General Affairs  
MicroPort Scientific Corporation  
Tel: (86)(21) 38954600  
Email: ir@microport.com